Erratum to: Evaluation of serum HER2-ECD levels in patients with gastric cancer [J Gastroenterol, DOI 10.1007/s00535-014-0941-3];Evaluation of serum HER2-ECD levels in patients with gastric cancer

Journal of Gastroenterology

Volumn 50, Issue 1, 2015, Pages 41-45

  Oyama, Katsunobu ^a   Fushida, Sachio ^a   Tsukada, Tomoya ^a   Kinoshita, Jun ^a   Watanabe, Toshifumi ^a   Shoji, Masatoshi ^a   Nakanuma, Shinichi ^a   Okamoto, Koichi ^a   Sakai, Seisho ^a   Makino, Isamu ^a   Nakamura, Keishi ^a   Hayashi, Hironori ^a   Inokuchi, Masafumi ^a   Nakagawara, Hisatoshi ^a   Miyashita, Tomoharu ^a   Tajima, Hidehiro ^a   Takamura, Hiroyuki ^a   Ninomiya, Itasu ^a   Kitagawa, Hirohisa ^a   Fujimura, Takashi ^a   Tajiri, Ryousuke ^a   Ooi, Akishi ^a   Ohta, Tetsuo ^a   more..

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Gastric cancer; HER2; Human epidermal growth factor receptor 2; Serum

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; BLOOD; CANCER STAGING; EXTRACELLULAR MATRIX; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; STOMACH NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; EXTRACELLULAR MATRIX; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 84893959711     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-014-0962-y     Document Type: Erratum

References (22)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82.
2. Cohen JA, Weiner DB, More KF, et al. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene. 1989;4:81–8.
3. Williams TM, Weiner DB, Greene MI, et al. Expression of c-erbB-2 in human pancreatic adenocarcinomas. Pathobiology. 1991;59:46–52.
4. Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014; 17:1–12.
5. Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16:273–8.
6. Terashima M, Ochiai A, Kitada K, et al. Impact of human epidermal growth factor receptor (EGFR) and ERBB2 (HER2) expressions on survival in patients with stage II/III gastric cancer, enrolled in the ACTS-GC study. J Clin Oncol. 2011;29:abstract 4013.
7. Bang YJ, Van Cutsem E, Feyereislova A, ToGA Trial Investigators, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.
8. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.
9. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797–805.
10. Lam L, McAndrew N, Yee M, et al. Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta. 2012;1826:199–208.
11. Ludovini V, Gori S, Colozza M, et al. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol. 2008;19:883–90.
12. Sugano K, Ushiama M, Fukutomi T, et al. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int J Cancer. 2000;89:329–36.
13. Greene FLPD, Fleming ID. American Joint Committee on cancer staging manual. 6th ed. Philadelphia: Springer; 2002.
14. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
15. Narita T, Seshimo A, Suzuki M, et al. Status of tissue expression and serum levels of HER2 in gastric cancer patients in Japan. Hepatogastroenterology. 2013;60:1083–8.
16. Kono K, Naganuma H, Sekikawa T, et al. Serum level of HER-2/neu in patients with gastric cancer: correlation with HER-2/neu overexpression in gastric carcinoma tissue. Tumour Biol. 2000;21:139–44.
17. Takehana T, Kunitomo K, Kono K, et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer. 2002;98:833–7.
18. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol. 2011;18:53–9.
19. Witzel I, Loibl S, Minckwitz GV. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Res Treat. 2010;123:437–45.
20. Zidan J, Dashkovsky I, Stayerman C, et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer. 2005;932:552–6.
21. Asgeirsson KS, Agrawal A, Allen C, et al. Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients. Breast Cancer Res. 2007;9:R75.
22. Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014;17:26–33.